May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
The Analgesic Effect of Topically Applied Nepafenac and Bromfenac Ophthalmic Solution on Normal Adult Eyes
Author Affiliations & Notes
  • R. A. Camillo
    Ophthalmology, New York Medical College at Westchester Medical Center, Valhalla, New York
  • G. W. Zaidman
    Ophthalmology, New York Medical College at Westchester Medical Center, Valhalla, New York
  • W. M. Liu
    Ophthalmology, New York Medical College at Westchester Medical Center, Valhalla, New York
  • Footnotes
    Commercial Relationships  R.A. Camillo, None; G.W. Zaidman, None; W.M. Liu, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 96. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. A. Camillo, G. W. Zaidman, W. M. Liu; The Analgesic Effect of Topically Applied Nepafenac and Bromfenac Ophthalmic Solution on Normal Adult Eyes. Invest. Ophthalmol. Vis. Sci. 2008;49(13):96. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Diclofenac, a widely used topical non-steroidal anti-inflammatory drug (NSAID), has an analgesic effect on the cornea. Different NSAID eye drops may have differing analgesic effects on the cornea. The authors evaluated nepafenac (Nevanac) and bromfenac (Xibrom) to determine their analgesic effect on normal adult eyes.

Methods: : In a prospective study, 30 patients were randomly assigned to receive either (1) placebo or nepafenac in each eye or (2) placebo or bromfenac in each eye. Patients were divided into 3 groups: Group A composed of 30 patients who received placebo, Group B composed of 15 patients who received nepafenac and Group C composed of 15 patients who received bromfenac. A Cochet-Bonnet aesthesiometer was used to test corneal sensation at baseline, prior to administration of any drops, and at 1 minute, 10 minutes and 30 minutes after instillation of placebo or medication.

Results: : Baseline corneal sensitivity for Groups A, B and C had mean of 58.3 (SD=3.56). Group A (placebo) at 1 minute had a mean sensation of 53.3 (SD=8.84), at 10 minutes a mean of 54.7 (SD 8.90) and at 30 minutes a mean of 55.5 (SD=8.23). Group B (nepafenac) at 1 minute had a mean sensation of 53.3 (SD=10.97), at 10 minutes a mean of 56.7 (SD=6.17) and at 30 minutes a mean of 56.3 (SD=4.81). Group C (bromfenac) at 1 minute had a mean sensation of 54.7 (SD=9.15), at 10 minutes a mean of 52.7 (SD 10.33) and at 30 minutes a mean of 53.3 (SD=7.94). All results were analyzed using a Student’s T-test. Group A (placebo) showed a statistically significant reduction (p<0.05) in corneal sensitivity at 1 and 10 minutes but not at 30 minutes when compared to baseline. Group B (nepafenac) did not show a statistically significant reduction in corneal sensation whether compared to baseline or to Group A (placebo) at any time point. Group C (bromfenac) showed a statistically significant (p<0.05) reduction in corneal sensitivity at 30 minutes when compared to baseline measurement of corneal sensation. Group C (bromfenac) did not show a statistically significant reduction in corneal sensitivity when compared to Group A (placebo). Group C (bromfenac) showed a trend towards reduction in corneal sensitivity at all time points when compared to Group A (placebo).

Conclusions: : The placebo showed analgesic effect at 1 and 10 minutes. Nepafenac did not have an analgesic effect when compared to baseline or to placebo at any time point. Bromfenac did have a potential analgesic effect at 30 minutes when compared to baseline and showed a trend towards reduction in corneal sensitivity at all time points when compared to placebo.

Keywords: cornea: clinical science • inflammation • ocular irritancy/toxicity testing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×